Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Phospho-Chk1 (Ser317) (F10) rabbit mAb
20 μL is enough antibody for at least 20 Western blots.
Customers Also Viewed
|Description||The act of DNA damaged response and cell cycle checkpoints requires the activation of four protein kinases that form the canonical ATR-Chk1 and ATM-Chk2 pathways. ATR activation requires the generation of structures containing single strand DNA (ssDNA) adjacent to double strand DNA (dsDNA). Such ssDNA is coated with replication protein A complex and attracts ATR (1,2). The accumulation of ATR to damage sites results in initial activation of ATR. ATR phosphorylates proteins at the ssDNA which are called checkpoint regulators. The accumulation and phosphorylation of these checkpoint regulators further stimulates the catalytic activity of ATR. ATR-induced Chk1 phosphorylation likely occurs at the sites of DNA damage on chromatin (3-5). The activated ATR phosphorylates Chk1 at Ser317 and Ser345 in its C-terminal regulatory domain. Phospho Chk1 is critical for DNA damage checkpoint activation, replication control, and cell viability (6-8). Functionally, ATR-mediated phosphorylation elevates phospho Chk1 catalytic activity. The N-terminal catalytic domain of Chk1 adopts an open kinase conformation and the deletion of C-terminal domain increases Chk1 catalytic activity.|
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Formulation||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Ser317 of human phospho Chk1|
|Validated Reactivity||Human, Mouse|
|Recommended Usage||1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|References||1. Caprelli ML, et al. (2013) Cell Cycle, 12: 916-22.
2. Capasso H, et al. (2002) J. Cell Sci. 115: 4555-64.
3. Carrassa L, et al. (2011) Cell Cycle 10: 2121-8.
4. Chen MS, et al. (2003) Mol. Cell Biol. 23: 7488-97.
5. Ciccia A, et al. Mol. Cell 40: 179-204.
6. Cimprich CA, (2014) Oncogene 33: 3351-60
7. Cremona CA, et al. (2014) Oncogene 33: 3351-60.
8. Niida H, et al. (2007) Mol. Cell Biol. 27: 2572-81.
Flow cytometric analysis of Hela cells secondary antibody only negative control (blue) or treated imatinib (red) or treated with pervanadate (green) using Phospho-Chk1 (S317) antibody Chk1S317-F10 0.1 µg/mL. Cat. #2151.
Peptide blocking flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFNα + IL4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Chk1 (S317) antibody Chk1S317-F10 0.1 µg/mL. Cat. #2151.
Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or 0.1 µg/mL of isotype control Cat. #2141 (orange) or treated with imatinib (red) or with pervanadate (green) using Phospho-Chk1 (S317) antibody Chk1S317-F10 at 0.1 µg/mL. Cat #2151.
Phospho-PTEN (Ser380/Thr382/383) (E4) rabbit mAbCatalog#: 2131
Phospho-RelB (Ser552) rabbit mAb SureLight®488 conjugateCatalog#: 2210
Phospho-Akt1 (Ser473) (C7) rabbit mAb PE conjugateCatalog#: 1132
Phospho-Stat5 (Tyr694) (G11) rabbit mAb APC conjugateCatalog#: 2329